Summary
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Official Title
A Phase I Study of FT819 in Subjects With B-cell Malignancies
Keywords
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia, Lymphoma, Leukemia, BCL, CLL, B-ALL, CAR-T, cellular therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, B-Cell Lymphoma, Cyclophosphamide, Bendamustine Hydrochloride, Fludarabine, Interleukin-2, Bendamustine, FT819 Step Fractionated Monotherapy, B-Cell Lymphoma, FT819 Step Fractionated Monotherapy, CLL, FT819 Step Fractionated Monotherapy, B-ALL